News View All News arrow-button

Nov 01, 2017

IFM’s Gary Glick Discusses Future of Innate Immunity in Nature Biotechnology

Nature Biotechnology 

IFM Therapeutics CEO and Co-Founder, Gary Glick, was interviewed as part of a story on inflammasomes as a chronic disease driver in Nature Biotechnology. View the full story, "Novartis Trial Validates Inflammasome As Chronic Disease Driver", on Nature.

*Please note a subscription to Nature is required to view the full article.

Media Contact

Amanda Sellers
Spectrum Science Communications